< Back to previous page


Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID)

Research Group

Lifecycle:1 Jan 2019 →  Today
Organisation profile:The "Centre for Health Economic Research & Modelling Infectious Diseases" (CHERMID) has extensive expertise in health economics, biostatistics and mathematical models. CHERMID is multidisciplinary, currently employing 14 researchers, often with multiple backgrounds (economics, medicine, mathematics, statistics, informatics, physics, biology and (bio/commercial) engineering). CHERMID conducts both conceptual-methodological and applied research. In health economics, such research includes developing: (1) international standards for the conduct and interpretation of health economic evaluations, particularly in relation to infectious diseases; (2) methods on dealing with uncertainty in health economic evaluation; (3) methods to identify determinants of health and health care consumption; (4) methods for health-related quality of life assessment; (5) surveys to analyse people's (a) risk perceptions of infectious diseases and vaccines ; (b) preferred criteria for health care prioritisation; (c) health care consumption; (d) health-related quality of life. Additionally, CHERMID develops methods to address infectious disease modelling challenges related to: (1) modelling between-host infectious disease transmission; (2) modelling within-host immunological reponse mechanisms; (3) integrating between-host transmission and within-host immunological dynamics in single models; (4) demonstrating model fit and validity; (5) computational optimization of individual-based models; (6) collecting and quantifying serological data and social mixing patterns relevant to transmission; (7) Integrating behavioural change based on risk perceptions in individual-based models. Numerous methodological and policy studies have been undertaken by CHERMID in various countries, including model, burden of disease and economic evaluation studies applied to influenza, respiratory syncytial virus (RSV), pneumococcus, measles, mumps, rubella, varicella- zoster, cytomegalovirus, pertussis, poliomyelitis, hepatitis A, hepatitis B, hepatitis C, HIV, meningococcal C, human papillomavirus, rotavirus, dengue, malaria and typhoid fever. The applications will focus in the coming years on measles-mumps-rubella, pneumococci, influenza and RSV.
Disciplines:Infectious diseases